Eli Lilly agreed to buy three vaccine developers in separate deals totaling up to $3.8 billion, expanding its infectious-disease portfolio beyond its established cardiometabolic franchises. The acquisitions include Vaccine Company (Bethesda), Curevo (Seattle), and LimmaTech Biologics (Zurich), with upfront terms not disclosed and milestone-driven ceilings depending on each transaction.